Kornimate/medical-research-clean huggingface dataset:
effects of education after colorectal cancer screening

Conditions: Healthy Lifestyle; Education

Summary: the aim of this study is to examine the effect of the education given to individuals undergoing colorectal cancer screening on their attitudes, beliefs and healthy lifestyle behaviors. this study was planned to be conducted as a prospective randomized controlled study in a family health center in istanbul. the universe of the research; the sample of individuals registered to the family health center will consist of a total of 70 individuals who meet the inclusion criteria for the study. patient diagnosis form, colorectal cancer screening attitude belief scale, healthy lifestyle behavior scale ii will be used to collect data. data will be collected at the first encounter, 1 month later, 3 months later, pre-test and post-test. in the research, individuals will be divided into two groups: intervention (n = 35) and control (n = 35). training will be provided to the intervention group.


Eligibility criteria:
inclusion criteria: * between 50-70 years old, * registered at the family health center, * able to speak turkish, * no diagnosis of psychiatric disease and no history of anxiolytic drug use, * they will have a fecal occult blood test for the first time, * positive result of fecal occult blood test, * faecal occult blood test was positive and had a colonoscopy, * those who have not been diagnosed with colorectal cancer as a result of colonoscopy, * individuals who volunteer to participate in the research exclusion criteria: * having had previous colon surgery, * individuals with a history of colorectal cancer will not be included in the study.

Keywords: colorectal cancer cancer screening healthy lifestyle education
amplatzer amulet china post market study (pms)

Conditions: Non-Valvular Atrial Fibrillation

Summary: the purpose of this study is to prospectively evaluate the safety and effectiveness of the amplatzer amulet laa occluder in a chinese patient population indicated for use of this device.

atrial fibrillation (af) is the most common sustained heart rhythm disorder. during af, chaotic electrical activity results in rapid, uncoordinated, and insufficient contractions of the atrial chambers. stagnation of blood flow in the left atrium (la) can lead to hypercoagulability. the left atrial appendage (laa), given its location and complex shape is often the primary site of stasis and thus increases the risk for thrombus formation. approximately 90% of all thrombi in patients with non-valvular af (nvaf) forming in the la originate in the laa. patients with nvaf are at an increased risk of systemic embolism and stoke due to the potential for clot forming in the laa. oac is the recommended first-line therapy for nvaf at increased risk of stroke, however, many patients have relative or absolute contraindications to taking oacs. laao offers a non-pharmacological option for stroke risk reduction in these patients unable to take oac. the amulet occluder is abbott's second-generation laa occlusion device. it received ce mark in 2013, and fda approval in august 2021. observational studies performed in multiple geographies show that the amulet occluder can be safely implanted with good procedural outcomes and reduce the risk of stroke as compared to a predicted rate without the need for anticoagulation in most patients. this led to the national medical products administration (nmpa) approval of the amulet occluder in 2020. the purpose of this study is to prospectively evaluate the safety and effectiveness of the amplatzer amulet laa occluder in a chinese patient population indicated for use of this device.

Eligibility criteria:
inclusion criteria: 1. documented non-valvular atrial fibrillation and contraindicated for long-term oral anticoagulation, or in those who are taking oral warfarin but still develop stroke or relevant events 2. meets the current device indications and per physician discretion for amulet implant 3. able to provide written informed consent prior to any study related procedures 4. 18 years of age or older at the time of enrolment exclusion criteria: 1. with the presence of intracardiac thrombus 2. with active endocarditis or other infections producing bacteremia 3. patients whose low risk of stroke (cha2ds2-vasc score is 0 or 1) or bleeding (has-bled score \< 3) 4. where placement of the device would interfere with any intracardiac or intravascular structures 5. has a life expectancy of less than 2 years due to any condition 6. currently participating or planning on participating during the follow up period of this study in a clinical study that includes an active treatment arm or a concurrent clinical study which may confound the results of this trial

Keywords: non-valvular atrial fibrillation nvaf amplatzer amulet
national registry of genetically triggered thoracic aortic aneurysms and cardiovascular conditions

Conditions: Marfan Syndrome; Turner Syndrome; Ehlers-Danlos Syndrome; Loeys-Dietz Syndrome; FBN1, TGFBR1, TGFBR2, ACTA2 or MYH11 Genetic Mutation; Bicuspid Aortic Valve Without Known Family History; Bicuspid Aortic Valve With Family History; Bicuspid Aortic Valve With Coarctation; Familial Thoracic Aortic Aneurysm and Dissections; Shprintzen-Goldberg Syndrome; Other Aneur/Diss of Thoracic Aorta Not Due to Trauma, <50yo; Other Congenital Heart Disease

Summary: the national registry of genetically triggered thoracic aortic aneurysms and cardiovascular conditions (gentac) was initiated in 2006 by the national heart, lung, and blood institute (nhlbi) and the national institute of arthritis and musculoskeletal and skin diseases (niams). gentac established a registry of 3706 patients with genetic conditions that may be related to thoracic aortic aneurysms and collected medical data and biologic samples. the study ended in september 2016. data and samples are available from nhlbi and requests should be made to biolincc. see the nhlbi website for more information: https://www.nhlbi.nih.gov/research/resources/gentac/.


Eligibility criteria:
eligible subjects must have one of the conditions listed below and be enrolled in-person at one of the participating clinical centers.contact the study coordinator at the location nearest you for more information about participation. * marfan syndrome * turner syndrome * ehlers-danlos syndrome * loeys-dietz syndrome * fbn1, tgfbr1, tgfbr2, acta2 or myh11 genetic mutation * bicuspid aortic valve without known family history * bicuspid aortic valve with family history * bicuspid aortic valve with coarctation * familial thoracic aortic aneurysm and dissectionsyes * shprintzen-goldberg syndrome * other aneurysms and dissections of the thoracic aorta not due to trauma, \<50yo * other congenital heart disease (e.g., tetralogy of fallot, coarctation) exclusion criteria: * inability of the patient, parent or guardian to give consent. * unwillingness to provide a blood or buccal specimen.

Keywords: marfan syndrome turner syndrome bicuspid aortic valve ehlers-danlos syndrome loeys-dietz syndrome aneurysm genetic aortic thoracic mutation dissection
optical spectroscopy for skin carcinomas' surgical management

Conditions: Carcinomatous or Polymorphous Skin Lesions

Summary: actinic keratosis are of utmost medical and economical interest because of their high prevalence (20 % of 60 year-old people and older in the northern hemisphere) and their important cosmetic impact as such actinic keratosis mostly appear on photo-exposed skin sites. the surgeon in charge of such lesions' removal (i) some actinic keratosis adjoining carcinoma to be resected therefore causing the problem of functional areas damaging (eyelids, lips, etc.) or (ii) numerous actinic keratosis localized away from carcinoma (photo-carcinogenesis field) faces the issue of clinical evaluation of such lesions: which ones will spontaneously regress (it is supposed to be the case for 20 % of such lesions);which ones will remain and which ones will develop into invasive carcinomas ? a non-invasive, non-traumatic, automated and real-time help for the clinical diagnosis orientation of such skin lesions could help improving diagnosis accuracy of the medical practitioner's visual inspection: * in terms of sensitivity in order to potentially decrease the number of actinic keratosis evolving towards invasive carcinoma, * in terms of specificity in order to potentially decrease useless resections and reduce resection margins and therefore reduce scars surface.


Eligibility criteria:
inclusion criteria: * adults, and * autonomous: enjoying full citizenship rights and full mental abilities, and * affiliated to a social security system, and * suffering from carcinomatous or polymorphous skin lesions that can be fully managed in an outpatient (ambulatory) surgery procedure. exclusion criteria: * carcinomatous or polymorphous skin lesions that require day admission, or * carcinomatous or polymorphous skin lesions for which resection margins are uncertain, or * naevomatous skin lesions and related skin pathologies.
promote q cardiac resynchronization therapy defibrillator (crt-d) and quartet left ventricular heart lead study

Conditions: Heart Failure

Summary: the objective of this study is to assess the safety and efficacy of the quartet™ lead and promote q® device system in a patient population indicated for cardiac resynchronization therapy.


Eligibility criteria:
inclusion criteria: * approved indication per acc/aha/hrs guidelines for implantation of a crt-d system for treatment of heart failure or lifethreatening ventricular tachyarrhythmia(s) * receiving a new implant or undergoing an upgrade from an existing icd or pacemaker implant with no prior lv lead placement. * ability to provide informed consent for study participation and is willing and able to comply with the prescribed follow-up tests and schedule of evaluations exclusion criteria: * have had a recent cva or tia within three months of enrollment * have a contraindication for an emergency thoracotomy * have a hypersensitivity to a single 1.0mg dose of dexamethasone sodium phosphate or short term contact with heparin * have a classification of status 1 for cardiac transplantation or consideration for transplantation over the next 3 months * have undergone a cardiac transplantation within 40 days of enrollment * have had a recent myocardial infarction, unstable angina or cardiac revascularization (ptca, stent or cabg) within 40 days of enrollment * are currently participating in a clinical investigation that includes an active treatment arm * are pregnant or planning to become pregnant during the duration of the study * have a life expectancy of less than 6 months due to any condition * are less than 18 years of age * are unable to comply with the follow up schedule

Keywords: crt heart failure lv leads
buccal bone resorption in immediate implants in thin and thick buccal plates of bone in esthetic zone

Conditions: Buccal Bone Thickness

Summary: to achieve esthetic immediate implants a minimum of adequate buccal bone thickness must be present. it was postulated that 2 mm of buccal bone thickness was needed to prevent recession of the buccal plate. however, this was reduced to 1 mm with more ongoing research. in a recent study postulated that a buccal bone thickness less than 1 mm could be sufficient. scarce literature was found that monitored the ridge alterations following implant placement. in regards to the controversies regarding the minimal initial buccal bone thickness required to perform immediate implant placement, our study aims to monitor the buccal bone thickness and soft tissue changes over a year from implant and prosthetic placement.


Eligibility criteria:
inclusion criteria: * subjects who have at least one unrestorable tooth in the esthetic zone that needs to be extracted. * subjects with healthy systemic condition. * availability of bone apical and palatal to the socket to provide primary stability. exclusion criteria: * patients with signs of acute infection related to the area of interest. * patients with habits that may jeopardize the implant longevity and affect the results of the study such as parafunctional habits. * smokers
self-screening of cognitive impairment in primary care

Conditions: Cognition Disorder; Alzheimer Disease

Summary: according to 2011 has recommendations, early detection of alzheimer disease is the major objective in order to allow an earlier care and support. these recommendations strengthen general practitioner role, who plays a key role in the identification of cognitively impaired patients. has recommendations are the use of mmse like test (mini mental state examination) at general practitioner office. a self-screening test, without medical presence, would allow a self-administered cognitive assessment by the patient. a review of the literature about self-administered cognitive tests has been realized. the self-administered gerocognitive examination (sage) has been chosen. it is a brief, valid and reliable cognitive assessment tool, rated on 22 points, which allows an early detection of cognitive impairment, with a sensitivity close to the mmse test. nevertheless, sage has never been tested at home without medical supervision. in this study, the investigators will determine if sage scores at home correlates with mmse scores at general practitioner office. patients with inclusion criteria will be recruited during the general practitioner consultation and will have a clinical assessment included mmse and clinical data collection. then, sage will be given to the patient in order to be completed at home without medical supervision and send to the general practitioner.


Eligibility criteria:
inclusion criteria: * subjects from three picard general practitioner's practice * 60 years old or more * patients who accept to complete the tests * with ou without cognitive complaint * patients able to read and write * affiliated to social security system exclusion criteria: * major visual disorders * legal safeguard * diagnosis of neuro-cognitive disorder

Keywords: cognition disorder alzheimer disease mmse sage
retrieve-ami study

Conditions: Myocardial Infarction; Thrombus; Coronary Artery Disease

Summary: heart attacks are caused by the sudden formation of a clot inside a diseased coronary artery which reduces blood flow beyond the blockage site. during conventional treatment of the blockage with what is known as a stent; a stainless steel tub that keeps the artery open, the clot that has formed is disrupted and is pushed further down leading to damage in smaller blood vessels supplying the heart muscle. this additional damage can lead to long-term heart muscle damage influencing recovery and wellbeing. the original concept that was tested to prevent this 'clot shower' was that of a suction device to withdraw the clot before stenting. however, this approach has not translated to patient benefit. amongst the reasons put forward for the inefficacy of the suction device was that it does not remove the entire clot as it does not interact with it. a new device that physically interacts with the clot and traps it before pulling it out - the stent retriever - is now routinely used in stroke therapy to remove clots in the arteries supplying the brain. this device has been successfully used as a last resort to remove clots in a small number of heart attacks. the investigators hypothesize that stent retriever therapy will be more effective in clot removal than the current standard of care; suction or stenting. to study this, the investigators propose the retrieve-ami randomised controlled trial.


Eligibility criteria:
inclusion criteria: * primary pci patient with st elevation myocardial infarction (stemi) * timi 0/1 flow at presentation * angiographic thrombus score ≥ 4 * vessel diameter at site of occlusion ≥ 3.0 mm (measured by quantitative coronary angiography) exclusion criteria: * female participant who is pregnant or lactating * participant with known hypersensitivity to nickel-titanium * unconscious at presentation * late presenter (pain to wire time \> 12 h) * class killip iii/iv and/or profound bradycardia (heart rate \< 40 bpm) * known history of kidney failure * ostial occlusion * highly tortuous vessel * highly calcified vessel * suspected (angiographically) spontaneous coronary artery dissection * stent thrombosis * previous stent implanted proximal to the occlusion site * previous coronary artery bypass graft surgery (cabg) * previous stemi/transient ischemic attack/stroke * known anaemia (hemoglobin \<9)

Keywords: myocardial infarction percutaneous coronary intervention stent retriever thrombus aspiration
yoga-cf (yoga outcomes get assessed in cystic fibrosis)

Conditions: Cystic Fibrosis

Summary: the goal of this clinical trial is to investigate the effects of yoga participation for adults with cystic fibrosis. the main question it aims to answer is: does participation in yoga affect health-related quality of life for adults with cystic fibrosis? researchers will compare a group completing a 12-week yoga programme alongside usual cystic fibrosis care, to a group completing usual care alone to see if the addition of yoga effects health-related quality of life.


Eligibility criteria:
inclusion criteria: diagnosis of cf (confirmed by standard criteria; (farrell et al. 2017)) sixteen years of age or over home internet access ability to complete questionnaires in english stable cf disease as judged by the investigator, a senior cf clinician exclusion criteria: inability to consent for treatment or measurement current participation in another interventional study current haemoptysis (greater than streaking in the sputum) known pregnancy at time of recruitment forced expiratory volume in 1 second (fev1) below 30% predicted at baseline use of ambulatory oxygen therapy, long-term oxygen therapy (ltot) or non-invasive ventilation current regular participation in yoga practice current neurological or musculoskeletal injury which would prevent completion of yoga diagnosis of osteoporosis (bone density z score \<-2.5) or history of spontaneous spinal fractures uncontrolled gastroesophageal reflux acute pulmonary exacerbation within 28 days of screening

Keywords: yoga
neuroqwerty: a transparent patient-centered outcome method to quantify parkinsonian motor signs for drug trials

Conditions: Parkinson Disease

Summary: the motor impairment produced by parkinson's disease (pd) is a significant and debilitating part of the condition. current methods to evaluate this impairment rely on subjective examinations. the investigators seek to develop an objective assessment of motor deficits by monitoring the participants natural interactions with a keyboard (on a computer or smart device). this approach provides a window to how the brain behaves during typical daily use of these devices, i.e. writing a report, sending an email or any other task performed on a digital device and thus has the potential to be used easily and regularly. (importantly, the data gathered are non-sensitive and based only on timing information). pd participants will be recruited during outpatient visits to pd clinics throughout the madrid metropolitan region. general entry criteria will be those patients who are scheduled to begin dopaminergic therapy, and own a home computer or laptop. the study will not impact on participants' standard clinical management other than by asking the participants to type for 15 minutes at each of the clinic visits, and installing the investigators proprietary software on their home computer. this software will collect keystroke data alone. (none of the actual information about what is being typed will be collected.) the keystroke data collected will be analyzed and compared with standard clinical metrics of therapeutic response, as well as the in-clinic typing data.


Eligibility criteria:
inclusion criteria: 1. participants between 18 years and 70 years (older subjects will be deemed eligible on an individual basis after review by the study team). 2. parkinson's disease (pd) diagnosis according to the united kingdom brain bank criteria. 3. pd patients without cognitive or psychiatric disturbances, as measured by the baseline assessment. 4. prescription of symptomatic therapy with l-dopa or dopamine agonists based on functional impairment attributed to pd. this will be based on the participant's physician criteria based on: * involvement of the dominant hand and/or upper limbs. * employed patients which the disease impairs their ability to work. 5. daily computer use \> 30 minutes exclusion criteria: 1. mild cognitive impairment or dementia. 2. psychiatric symptoms 3. expected or current use of sedative medication (benzodiazepines, opiates, antihistaminergic drugs). 4. neuroleptic use. 5. history of parkinsonism for the controls. 6. severe osteo-articular problems with upper limb functional limitation (amputations, severe osteo-arthritis). 7. alcohol risk use (\>40 gr/day or 4 standard drinks for male / \>24gr/day or 2 standard drinks for female). 8. narcolepsy or other sleep disorder producing hypersomnia (obstructive apnea, acute confusional states). 9. any other life- threatening condition (advanced cancer, severe hepatic or renal insufficiencies.

Keywords: hypokinesia patient outcome assessment
cognitive intervention to improve memory in heart failure patients

Conditions: Heart Failure NYHA Class II; Heart Failure NYHA Class III; Heart Failure NYHA Class I

Summary: cognitive intervention to improve memory in heart failure patients

a three arm randomized controlled trial of 276 heart failure patients.

Eligibility criteria:
inclusion criteria: * at least 21 years of age * understands english * has access to a telephone * hears normal conversation * for patients with hearing aids, able to wear and hear through headsets * diagnosis of chronic heart failure, stage c, nyha i, ii or iii * receiving guideline derived medical therapy * heart failure validated by echocardiography or other method in past 2 years * able to read a computer screen with or without glasses or lenses exclusion criteria: * history of drug or alcohol abuse or major psychiatric diagnosis present before the heart failure diagnosis * alzheimer or other dementia diagnosis or central nervous system degenerative disorder * terminal cancer * patients with baseline montreal cognitive assessment (moca) score of less than 19 supplement eligibility: first 144 patients randomized in the parent trial.

Keywords: heart failure cognition in heart failure
four or six weeks of immobilization in the conservative treatment of distal radius fractures in elderly population?

Conditions: Distal Radius Fracture

Summary: the purpose of this study is to compare if there are differences in wrist function and pain after a distal radius fracture treated conservatively with immobilization for 4 or 6 weeks in elderly patients after six months of follow-up.


Eligibility criteria:
inclusion criteria: * patients older than 65 years with a low energy distal radius fracture * intra or extraarticular distal radius fracture (a2, a3, c1, c2) * acceptable primary reduction (dorsal inclination \<10º, radial shortening \<3mm, articular gap \<2mm) exclusion criteria: * history of ipsilateral fracture * bilateral fracture * open fracture * other concomitant fracture (except ulnar styloid fracture) * fracture ao b * previous surgeries in this area * dementia